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Background: The Eurocare-4 (2000–2002) period analysis docu-
ments a mean European age-adjusted 5-year relative breast can-
cer survival of 79% with higher individual figures for Finland
(85.7%), Norway (84.1%) and Sweden (86.3%) (Lancet Oncol
2007;8:784–96). The corresponding mean figure for England was
77.8%. We now compare these predicted survival estimates with
actual age-adjusted relative 5-year breast cancer overall survival
for women diagnosed with invasive breast cancer in the East of
England from 2000 to 2002.
Method: The East of England covers a population of 5.5 million
people. Five-year age-adjusted relative breast cancer survival was
calculated overall, and in specific age groups, for 10,787 women
with invasive breast cancer diagnosed from 2000 to 2002 in the
East of England for comparison with the results from the Euro-
care-4 study.
Results:
Age-adjusted 5-year relative breast cancer survival in East of
England for period 2000–2002.
Age group Number of patients Relative survival 95% CI
45–54 2563 87.5% 86.1–88.9
55–64 2945 89.5% 88.1–90.9
65–74 2335 83.9% 81.8–86.1
75+ 2944 73.3% 70.1–76.4
All women 10,787 82.5% 81.4–83.6
Conclusion: These data confirm breast cancer survival rates for
East of England that are close to European best figures for women
aged 45–64. The mean survival of 82.5% for all women however is
being reduced by worse survival in women aged 65+ and a strategy
that ensures optimal breast cancer treatment for women in this age
group should allow the mean survival to improve even further.
doi:10.1016/j.ejcsup.2010.06.053
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Background: Despite being an important health issue, breast
cancer in older women is under-researched. This study aimed
to identify how CGA may be linked to treatment decision making.
Methods: Women P70 years with newly diagnosed primary
breast cancer in Nottingham were invited to take part. Decision
for a particular treatment was made between the clinical team
and the patient, and this was not part of the study. Each patient
then completed an established CGA tool – a multi-dimensional
questionnaire incorporating information on demographics,
mood, social activities and support, medication, functional sta-
tus, cognition, nutritional state and co-morbidities.
The study is ongoing. At this preliminary analysis, 20 patients
(aged 70–87) were recruited from different treatment groups
(mastectomy n = 8, breast conserving surgery, n = 4, primary
endocrine therapy (PET) n = 7, primary radiotherapy n = 1).
Results: Compared to patients undergoing surgery, the PET
group was found to be older (median age 85 versus 76). Patients
on PET also reported having lower median physical functioning
(7.5 versus 11.5) and social support (66.67 versus 89.95) scores,
mood levels (67.65 versus 85.29) and more co-morbidities (median
4 versus 2).
Conclusions: Using a CGA tool may be beneficial in guiding
treatment decision. This ongoing study may establish a tool spe-
cific to the context of older women with primary breast cancer.
This could then become part of routine consultation and may
help identify patients who would require input of a geriatrician.
When combined with quality of life measures and biological
information, there is potential to provide a holistic approach to
this under-served population.
doi:10.1016/j.ejcsup.2010.06.054
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Introduction: Understanding the mechanisms of drug resis-
tance is important to improve and deliver effective therapy.
MicroRNAs (miRNA) are small RNA molecules that regulate gene
expression, hence we hypothesised that gene silencing, by altered
miRNA expression, causes docetaxel resistance.
Methods: Quantitative PCR-based miRNA arrays were used to
examine the role of miRNAs in acquired resistance of breast cancer
cells (MCF-7 and MDA-MB-231) to docetaxel. Quantitative PCR and
western analysis were used to measure target gene mRNA and pro-
tein expression, respectively. MicroRNA expression was modulated
and docetaxel response was measured by cell viability assay.
Results: We found 299 and 226 miRNAs altered in MCF-7 and
MDA-MB-231 docetaxel-resistant cells, respectively. Only miRNA
alterations that reached statistical significance, which targeted
experimentally validated genes involved in cell cycle, apoptosis
or drug resistance, were selected for further investigation. Doce-
taxel resistance was associated with increased expression of
miR-34a and miR-141 and decreased expression of miR-7, miR-
16, miR-30a, miR-125a-5p, miR-126 and miR-429. Computational
target prediction revealed 11 candidate genes targeted by these
miRNAs. Quantitative PCR and western analysis confirmed
decreased expression of only two genes, BCL2 and cyclinD1, in
docetaxel-resistant cells, which are both targeted by miR-34a.
Inhibition of miR-34a enhanced response to docetaxel in MCF-7
docetaxel-resistant cells whereas overexpression of miR-34a con-
ferred resistance in MCF-7 docetaxel-sensitive cells. Modulation
of miR-34a expression was correlated with expected BCL2 and
cyclinD1 protein expression changes.
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